NEW YORK, NY / ACCESSWIRE / March 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of NantHealth, Inc. (“NantHealth”) (NASDAQ: NH) (1) pursuant and/or traceable to the Company’s initial public offering on or about June 1, 2016; and/or (2) between June 1, 2016 and March 6, 2017. You are hereby notified that Levi & Korsinsky has commenced the securities class action lawsuit Shafik v. NantHealth, Inc., et al. (Case No. 2:17-cv-01940-DMG-SS) in the USDC for the Central District of California. To get more information go to:

http://www.zlk.com/pslra/nanthealth-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose: (1) that Company founder Patrick Soon-Shiong had donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; (2) that, as such, the Company and Soon-Shiong participated in the violation of federal tax laws – exposing the Company to possible civil and criminal liability; (3) that the Company improperly recorded orders received from the University of Utah as GPS Cancer test orders; and (4) that, as a result, the Company reported false and inflated GPS Cancer order figures for the third quarter of 2016.

If you suffered a loss in NantHealth you have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458357

VANCOUVER, BC / ACCESSWIRE / March 28, 2017 / David H. Brett, President & CEO, EnGold Mines Ltd., (TSXV: EGM) (“EnGold” or the “Company”) reports that the two drills exploring a new copper/silver/gold discovery at its 100% owned Lac La Hache Property have both intersected broad intervals of intensely mineralized material that is visually similar to the discovery hole G16-01. Holes G17-03, collared 50 metres (“m”) east of discovery hole G16-01, & G17-04, collared 50 m west of G16-01, intersected 24 m and 13 m respectively at the same stratigraphic levels at approximately 335 m downhole. The holes are vertical and intercepts are believed to be true width. The mineralized core will be logged and assayed on a rush basis. Both drill holes will continue to their target depth of approximately 450 m.

“The new drill information confirms the stratabound nature and size potential of the skarn-style mineralization we observed in the discovery hole,” said VP of Exploration Rob Shives, P.Geo. “The newly commissioned gravity survey is proceeding and the data from this work will provide additional guidance for our drill program.”

“These strong step-out holes at the new discovery area are very encouraging,” said EnGold President & CEO David Brett. “Our exploration team is growing and continues to do excellent work covering not one but two high-priority targets at the Lac La Hache Property, where assay results from the Aurizon Gold zone are also pending.”

Following the completion of holes G17-03 & G17-04, EnGold plans a brief pause in the drill campaign to allow time for assay results to come in, avoid difficult spring break-up conditions, enable new geophysical data to be processed and analyzed, and provide time to plan and staff-up for what management expects an intensely busy rest of 2017. Drilling is expected to resume April 19th following the Easter weekend.

About EnGold

EnGold is focused on finding and developing mining operations at its 100% owned mineral property located near the town of Lac La Hache in BC’s prolific Cariboo mining region. EnGold’s corporate philosophy rests on three interdependent pillars: Environment, Engagement and Gold. Through sound environmental stewardship, commitment to transparent engagement with local communities, the Company is dedicated to driving exceptional shareholder and stakeholder value by discovering and developing mineral resources.

About the Lac La Hache Property

The advanced stage property lies within BC’s Quesnel Trough mineral belt, which hosts several past and currently producing copper/gold/silver mines, including nearby Imperial Metals’ Mount Polley copper-gold mine and New Gold Inc.’s New Afton copper-gold mine. The Company has drilled numerous prospects on the property, including Spout copper-magnetite-gold-silver deposit (for which a resource calculation has been reported and supported by an NI43-101 Technical Report), the gold-rich Aurizon gold-copper-silver prospect and recent new discoveries with porphyry and skarn copper/gold potential. Supported by significant local infrastructure including powerlines, all season road access, rail and other amenities, the Lac La Hache project demonstrates excellent logistics for resource extraction.

Rob Shives P.Geo., VP Exploration and a Qualified Person as defined under National Instrument 43-101, has reviewed and approved the technical content of this release.

Engold Mines Ltd.

Per/

David Brett, MBA
President & CEO

For further info contact David Brett, 604-682-2421 or david@engold.ca

This news release may contain “forward-looking statements”. Readers are cautioned that any such statements are not guarantees of future performance and that actual development or results may vary materially from those in these “forward looking statements.”

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Engold Mines Ltd.

ReleaseID: 458362

IRVINE, CA / ACCESSWIRE / March 28, 2017 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Platinum Pari-Mutuel Holdings Inc. (“Platinum” or the “Company”) (OTC PINK: PPMH). Investors who purchased or otherwise acquired shares between July 12, 2016 and February 15, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the May 2, 2017 lead plaintiff motion deadline.

If you purchased shares of Platinum during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, Platinum issued materially false and/or misleading statements and/or failed to disclose that: Platinum’s press releases and financial information lacked veracity; that the Company’s disclosure controls and procedures were inadequate; and that as a result of the above, Platinum’s public statements were materially false and misleading at all relevant times. On February 16, 2017, the Securities and Exchange Commission prevented Platinum from trading due to questions regarding the accuracy of its press releases and the financial information Platinum offered the public. The SEC clarified that these questions concern the valuation of recent corporate acquisitions and forecasts for future revenues.

If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458356

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies, is issuing a comprehensive report with no obligation on MyDx Inc. (OTCQB: MYDX). MyDx Inc. is a science and technology company that owns MyDx™, which “is a simple and affordable portable analyzer that will detect the chemicals we cannot see.” This analyzer will help detect and analyse how consumers feel in direct relation to the profile of cannabis. According to the company, “MyDx™ uses nanotechnology to accurately measure chemicals” and its aim is to make people live better by understanding the components in the food and drinks that they consume. When people are aware of the specific contents of what they eat and how it makes them feel, they can develop a diet that makes them happier, overall.

MYDX is focused on developing a technology that analyses the effects that our consumption (food, drugs, alcohol) has on us, and this information will “empower you to live a healthier life by revealing the purity of what you eat, drink, and inhale in the palm of your hands, and in real time.”

How close is MyDx technology to going to market? READ MORE.

Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/mydx/.

The Company has experienced a series of changes to its management, which have proved disruptive, and has had adverse effects on its financial conditions including, but not limited to, inability to timely file quarterly reports. MyDx is exposed to key person risk.

The following report discusses these changes in management and risks involved: READ MORE.

Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/mydx/.

DISCLOSURE

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles, and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated, directly or indirectly, for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst. For further information on analyst credentials, please email editor@tradersnewssource.com. Sina Yilu, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 458361

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Natus Medical Incorporated (“Natus”) (NASDAQ: BABY) between October 16, 2015 and April 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. To get more information go to:

http://www.zlk.com/pslra/natus-medical-incorporated?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis.

If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458353

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Gigamon Inc. (“Gigamon”) (NYSE: GIMO) between October 27, 2016 and January 17, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. To get more information, go to: http://www.zlk.com/pslra/gigamon-inc?wire=1, or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about Gigamon’s business, operations, and prospects, including that: (1) Gigamon was experiencing reduced product bookings in its North America West region; (2) several of Gigamon’s significant customers were deferring purchasing decisions into 2017; (3) Gigamon failed to properly include these trends in its financial guidance; and (4) as a result, Defendants’ statements about Gigamon’s business, operations, and prospects, including statements about its revenue guidance, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Gigamon, you have until March 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458352

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Egalet Corporation (“Egalet”) (NASDAQ: EGLT)
between December 15, 2015 and January 9, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Mineff v. Egalet Corporation, et al. (Case No. 2:17-cv-00390-MMB) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information, go to: http://www.zlk.com/pslra/egalet-corporation, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, among other allegations, throughout the Class Period, Egalet made materially false and/or misleading statements concerning its lead product, ARYMO ER, and the likelihood the product would receive oral abuse-deterrent labeling.

Take Action: if you suffered a loss in Egalet, you have until March 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458351

DALLAS, TX / ACCESSWIRE / March 28, 2017 / North American Cannabis Holdings, Inc. (OTC PINK: USMJ), commonly known as USMJ, today announced the Company will officially launch its AmeriCanna Cafe at the upcoming Southwest Cannabis Conference and Expo April 22-23 in Fort Worth, Texas. USMJ acquired a City Blends Smoothie Cafe licensed operator in 2015 to use as the foundation to pilot the AmeriCanna Cafe fast casual concept restaurant. After almost two years of product innovation and experimentation and contract negotiation with vendors and partners, USMJ is now ready to launch the AmeriCanna Cafe. The Southwest Cannabis Conference and Expo will be the first tradeshow venue where USMJ displays and demonstrates the restaurant features seeking restaurant investors and operators interested in opening AmeriCanna Cafes in partnership with USMJ.

AmeriCanna Cafe Products On Display To Include EVERx CBD and Alkaline Waters

The AmeriCanna Café pilot has included the marketing of specific products and product lines. Two notable products are the EVERx CBD Infused Bottled Water and EVERx Alkaline Bottled Water, both developed by Puration, Inc. (OTC PINK: PURA) in partnership with Alkame Holdings, Inc. (OTC PINK: ALKM). EVERx CBD Infused Bottled Water and EVERx Alkaline Bottled Water were recently formally launched at Arnold Schwarzenegger’s Annual Arnold Sports Festival.

Come to the Southwest Cannabis Conference and Expo in Fort Worth, Texas on April 22 and 23 for a free CBD infused AmeriCanna Cafe smoothie and to learn more about AmeriCanna Cafe restaurant partnership opportunities.

Learn More About USMJ: growusmj.com
Learn More About PURA: purationinc.com
Learn More About EVERx: drinkeverx.com
Learn More About ALKM: alkamewater.com

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

North American Cannabis Holdings Contact:

Steven Rash
Phone: +1-972-528-0162
Email: Info@growusmj.com

SOURCE: North American Cannabis Holdings

ReleaseID: 458354